Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NV 5138

Next Previous
Drug Profile

NV 5138

Alternative Names: NV-5138; SPN 820; SPN-820/821; SPN-821

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Navitor Pharmaceuticals; X-Chem
  • Developer Navitor Pharmaceuticals; Supernus Pharmaceuticals
  • Class Antidepressants; Pentanoic acids; Small molecules
  • Mechanism of Action MTORC1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Depressive disorders; Major depressive disorder

Most Recent Events

  • 15 Feb 2024 Phase-II clinical trials in Major depressive disorder (Adjunctive treatment) in USA (PO) (NCT06235905)
  • 08 Nov 2023 Supernus Pharmaceuticals plans a phase II trial for Major depressive disorders before end of 2023
  • 28 Feb 2022 Phase-II clinical trials in Depressive disorders (Treatment-resistant) in USA (PO) (NCT05066672)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top